SCHEMBL762355

SCHEMBL762355

CN1C(=O)CCc2ccc(C(C)(C)C)cc21

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 2/20 0.44
TRPV1 Q8NER1 5/20 0.41
CYP11B1 P15538 3/20 0.40
CYP11B2 P19099 3/20 0.40
CYP19A1 P11511 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP17A1 P05093 1/20 0.40
NR1H3 Q13133 1/20 0.39
ALDH1A1 P00352 2/20 0.39
ALOX5 P09917 1/20 0.39
CYP3A4 P08684 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
TMEM97 Q5BJF2 1/20 0.38
SRD5A1 P18405 1/20 0.38
CREBBP Q92793 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL761237 0.86 CYP11B2 (0.50) TRIM24CYP11B1CYP11B2CYP19A1CYP1A2
SCHEMBL21024044 0.86 NR1H3 (0.39) TRIM24NR1H3ALDH1A1SMN1; SMN2CREBBP
SCHEMBL25536869 0.79 NR1H3 (0.39) NR1H3ALDH1A1SMN1; SMN2
SCHEMBL23051012 0.79 TP53 (0.50) TRIM24CYP11B1CYP11B2CYP19A1CYP1A2
SCHEMBL10890659 0.79 TRIM24 (0.46) TRIM24TRPV1CYP11B1CYP11B2CYP19A1
SCHEMBL5023390 0.79 SRD5A1 (0.54) TRIM24TRPV1CYP11B1CYP11B2CYP19A1
SCHEMBL29678322 0.78 ALDH1A1 (0.38) CYP1A2NR1H3ALDH1A1SMN1; SMN2
SCHEMBL11263558 0.77 SRD5A1 (0.55) TRIM24TRPV1CYP1A2CYP3A4SMN1; SMN2
SCHEMBL1439563 0.77 TRIM24 (0.45) TRIM24TRPV1CYP11B1CYP11B2CYP19A1
SCHEMBL8556641 0.77 SRD5A1 (0.55) TRIM24TRPV1CYP11B1CYP11B2CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 US disclosed
US-20230242531-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-08-03 US disclosed
US-11168070-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2021-11-09 US disclosed
US-20200399244-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2020-12-24 US disclosed
US-20200239458-A1 INHIBITORS OF PROTEIN KINASES ALEXION PHARMACEUTICALS, INC. 2020-07-30 US disclosed
US-10696655-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2020-06-30 US disclosed
US-20190152949-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2019-05-23 US disclosed
US-20180186783-A1 INHIBITORS OF PROTEIN KINASES ALEXION PHARMACEUTICALS, INC. 2018-07-05 US disclosed
US-20180186783-A1 INHIBITORS OF PROTEIN KINASES ALEXION PHARMACEUTICALS, INC. 2018-07-05 US disclosed
US-9868729-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2018-01-16 US disclosed
US-20130165431-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-8349860-B2 Inhibitors of syk and JAK protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2013-01-08 US disclosed
US-8318755-B2 Inhibitors of SYK and JAK protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2012-11-27 US disclosed
US-20120130073-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-24 US disclosed
US-20120129867-A1 INHIBITORS OF PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-24 US disclosed
US-20120101275-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. (US) 2012-04-26 US disclosed
US-8138339-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2012-03-20 US disclosed
US-8063058-B2 Inhibitors of syk and JAK protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2011-11-22 US disclosed
US-20100048567-A1 Inhibitors of syk and JAK protein kinases PORTOLA PHARMACEUTICALS INC. (US) 2010-02-25 US disclosed
US-20090318407-A1 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2009-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318407-A1 Inhibitors of protein kinases SYK, BTK, JAK1 TRIM24 2490/4885TRPV1 4221/4885CYP11B1 1249/4885
US-20230242531-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP TRIM24 4301/4885TRPV1 1657/4885CYP11B1 1560/4885
US-20130165431-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES SYK, BTK, JAK1 TRIM24 2516/4885TRPV1 3411/4885CYP11B1 854/4885
US-20120129867-A1 INHIBITORS OF PROTEIN KINASES SYK, BTK, JAK1 TRIM24 2490/4885TRPV1 4221/4885CYP11B1 1249/4885
US-20120130073-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES SYK, BTK, JAK1 TRIM24 2516/4885TRPV1 3411/4885CYP11B1 854/4885
US-20120101275-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES SYK, BTK, JAK1 TRIM24 2516/4885TRPV1 3411/4885CYP11B1 854/4885
US-20200239458-A1 INHIBITORS OF PROTEIN KINASES SYK, BTK, JAK1 TRIM24 2490/4885TRPV1 4221/4885CYP11B1 1249/4885
US-20180186783-A1 INHIBITORS OF PROTEIN KINASES SYK, BTK, JAK1 TRIM24 2490/4885TRPV1 4221/4885CYP11B1 1249/4885
US-20200399244-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC3 TRIM24 2652/4885TRPV1 1975/4885CYP11B1 1800/4885
US-20100048567-A1 Inhibitors of syk and JAK protein kinases SYK, BTK, JAK1 TRIM24 2516/4885TRPV1 3411/4885CYP11B1 854/4885
US-20190152949-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC11 TRIM24 2581/4885TRPV1 1737/4885CYP11B1 1749/4885
US-11168070-B2 Therapeutic compounds and uses thereof EP300, HDAC1, HDAC11 TRIM24 2581/4885TRPV1 1737/4885CYP11B1 1749/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP TRIM24 4058/4885TRPV1 1596/4885CYP11B1 1168/4885
US-10696655-B2 Therapeutic compounds and uses thereof EP300, HDAC1, HDAC11 TRIM24 2581/4885TRPV1 1737/4885CYP11B1 1749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.